Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thymoma 1Thymic epithelial tumor 1Neoplasm, Residual 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Bevacizumab 25Fluorouracil 23Leucovorin 22Cetuximab 22Oxaliplatin 19pembrolizumab 14Specimen Handling 11Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8Biopsy 7atezolizumab 6fludarabine 5encorafenib 5Pemetrexed 5Panitumumab 5HMPL-013 5Gemcitabine 5Folfox protocol 5Cisplatin 5Carboplatin 5trifluridine tipiracil drug combination 4balstilimab 4Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × AP 1903 reagent × 30 days × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡